Supplementary Fig. 8.
Validation of SB525334 inhibition by immunofluorescence in human NPCs. Fixed Q21 and Q109 NSCs at baseline, and following treatment with 100 ng/ml TGFβ1, either with or without prior treatment with SB525334, and stained with antibodies against A. SMAD2 and B. SMAD3. Scale bar = 20 μM. Figures representative of multiple images, N = 3